AR041275A1 - Compuestos de isotiazol e isoxazol como inhibidores del factor de crecimiento transformador (tgf) y composicion farmaceutica - Google Patents

Compuestos de isotiazol e isoxazol como inhibidores del factor de crecimiento transformador (tgf) y composicion farmaceutica

Info

Publication number
AR041275A1
AR041275A1 ARP030103359A ARP030103359A AR041275A1 AR 041275 A1 AR041275 A1 AR 041275A1 AR P030103359 A ARP030103359 A AR P030103359A AR P030103359 A ARP030103359 A AR P030103359A AR 041275 A1 AR041275 A1 AR 041275A1
Authority
AR
Argentina
Prior art keywords
alkyl
heteroaryl
phenyl
amino
heterocyclyl
Prior art date
Application number
ARP030103359A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR041275A1 publication Critical patent/AR041275A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compuestos de isotiazol e isoxazol, incluyendo derivados de los mismos, intermedios para prepararlos, composiciones farmacéuticas que los contienen y su uso medicinal. Los compuestos de la presente son potentes inhibidores de la ruta de senalizacióndel factor de crecimiento transformador ("TGF")-beta. Son útiles en el tratamiento de diversas patologías relacionadas con TGF incluyendo, por ejemplo, cáncer y enfermedades fibróticas. Reivindicación 1: Un compuesto de fórmula (A) o una sal,profármaco. hidrato, tautómero o solvato farmacéuticamente aceptable del mismo caracterizado porque X es O o S; R1 es un anillo saturado, insaturado o aromático C3-20, mono-, bi- o policíclico que contiene, opcionalmente, al menos un heteroátomoseleccionado del grupo constituido por N, O y S; R1 puede estar opcionalmente sustituido independientemente además con al menos un resto seleccionado independientemente del grupo constituido por: carbonilo, halo, haloalquilo C1-6, perhaloalquiloC1-6, perhaloalcoxi C1-6, alquilo C1-6, alquenilo C2-6. alquinilo C2-6, hidroxi, oxo, mercapto, (alquil C1-6)tio, alcoxi (C1-6), arilo (C5-10) o heteroarilo (C5-10), aril(C5-10)oxi o heteroaril (C5-10)oxi, aril(C5-10)alquilo (C1-6) oheteroaril(C5-10)alquilo(C1-6), aril(C5-10)alcoxi(C1-6) o heteroaril(C5-10)alcoxi(C1-6), HO-(C=O)-, éster, amido, éter, amino, aminoalquilo C1-6, (alquil C1-6)aminoalquilo C1-6, dialquil (C1-6)aminoalquilo (C1-6), (heterociclil C5-10) alquilo(C1-6), (alquil C1-6) y dialquil (C1-6)amino, ciano, nitro, carbamoilo, alquil (C1-6) carbonilo, alcoxi (C1-6)carbonilo, alquil (C1-6)aminocarbonilo, dialquil (C1-6)aminocorbonilo, aril (C5-10)carbonilo, aril (C5-10)oxicarbonilo, alquil(C1-6)sulfonilo, y aril (C5-10)sulfonilo; cada R3 se selecciona independientemente del grupo constituido por H, halo, haloalquilo C1-6, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, perhaloalquilo C1-6, fenilo, heteroarilo C5-10, heterociclilo C5-10,cicloalquil C3-10, hidroxi, alcoxi C1-6, perhaloalcoxi C1-6, fenoxi, heteroaril (C5-10)-O-, heterociclil (C5-10)-O-, cicloalquil (C3-10)-O-, alquil (C1-6)-S-, alquil (C1-6)-SO2-, alquil (C1-6)-NH-SO2-,-O2N, -NC, amino, -Ph(CH2)1-6HN, -alquil(C1-6)-HN, alquil (C1-6)amino, [alquil (C1-6)]2-amino, alquil (C1-6)-SO2-NH-, amino-(C=O), -amino-O2S-, alquil (C1-6)-(C=O)-NH-, alquil (C1-6)-(C=O)-[(alquil C1-6))-N]-, fenil-(C=O)-NH, fenil-(C=O)-[alquil (C1-6)-N]-, alquil (C1-6)-(C=O)-,fenil-(C=O)-, heteroaril (C5-10)-(C=O)-, heterociclil (C5-10)-(C=O)-, cicloalquil (C3-10)-(C=O)-, HO-(C=O)-, alquil (C1-6)-O-(C=O)-, H2N-(C=O)-, alquil (C1-6)-NH-(C=O)-, [alquil (C1-6)]2-N-(C=O)-, fenil-NH-(C=O)-, fenil-[(alquil (C1-6))-N]-(C=O)-,heteroaril (C5-10)-NH-(C=O)-, heterociclil (C5-10)-NH-(C=O)-, cicloalquil (C3-10)-NH-(C=O)- y alquil (C1-6)-(C=O)-O-; en el que alquilo, alquenilo, alquinilo, fenilo, heteroarilo, heterociclilo, cicloalquilo, alcoxi, fenoxi, amino de R3 estáopcionalmente sustituido por al menos un sustituyente seleccionado independientemente entre alquilo C1-6, alcoxi C1-6, haloalquilo C1-6, halo, H2N-, Ph(CH2)1-6-HN, y (alquil C1-6)-HN; s es un entero de 1 a 5; y R4 se selecciona del grupo constituidopor H, halo, haloalquilo(C1-6), alquilo(C1-6), alquenilo(C2-6), alquinilo(C2-6), perhaloalquilo(C1-6), fenilo, heteroarilo(C5-10), heterociclilo(C5-10), cicloalquilo(C3-10), hidroxi, alcoxi(C1-6), perhaloalcoxi C1-6, fenoxi, heteroaril (C5-10)-O-,heterociclil (C5-10)-O-, cicloalquil (C3-10)-O-, alquil (C1-6)-S, alquil (C1-6)-SO2-, alquil (C1-6)-NH-SO2-, -O2N, -NC, amino, Ph(CH2)1-6NH, (alquil C1-6)-NH, (alquil C1-6)amino, [alquil (C1-6)]2-amino, alquil (C1-6)-SO2-NH, amino-(C=O), amino-SO2-,alquil (C1-6)-(C=O)-NH, alquil (C1-6)-(C=O)-(alquil (C1-6))-N-, fenil-(C=O)-NH, fenil-(C=O)-[alquil (C1-6)-N]-, alquil (C1-6)-(C=O)-, fenil-(C=O)-, heteroaril (C5-10)-(C=O)-, heterociclil (C5-10)-(C=O)-, cicloalquil(C3-10)-(C=O)-, HO-(C=O)-, alquil(C1-6)-O-(C=O)-, H2N-(C=O)-, alquil (C1-6)-NH-(C=O)-, (alquil (C1-6))2-N-(C=O)-, fenil-NH-(C=O)-, fenil[(alquil (C1-6))-N]-(C=O)-, heteroaril (C5-10)-NH-(C=O)-, heterociclil (C5-10)-NH-(C=O)-, cicloalquil (C3-10)-NH-(C=O)-, y alquil (C1-6)-(C=O)-O;en el que alquilo, alquenilo, alquinilo, fenilo, heteroarilo, heterociclilo, cicloalquilo, alcoxi, fenoxi y amino de R4 está opcionalmente sustituido por al menos un sustituyente seleccionado independientemente del grupo constituido por alquiloC1-6, alcoxi C1-6, haloalquilo C1-6, halo, H2N-, Ph(CH2)1-6-NH, alquil (C1-6)-NH-.
ARP030103359A 2002-09-18 2003-09-16 Compuestos de isotiazol e isoxazol como inhibidores del factor de crecimiento transformador (tgf) y composicion farmaceutica AR041275A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41213102P 2002-09-18 2002-09-18
US48458003P 2003-07-02 2003-07-02

Publications (1)

Publication Number Publication Date
AR041275A1 true AR041275A1 (es) 2005-05-11

Family

ID=32033584

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030103359A AR041275A1 (es) 2002-09-18 2003-09-16 Compuestos de isotiazol e isoxazol como inhibidores del factor de crecimiento transformador (tgf) y composicion farmaceutica

Country Status (25)

Country Link
US (1) US7030125B2 (es)
EP (1) EP1542995A1 (es)
JP (1) JP2006506443A (es)
KR (1) KR20050057441A (es)
CN (1) CN1681809A (es)
AP (1) AP2005003262A0 (es)
AR (1) AR041275A1 (es)
AU (1) AU2003263431A1 (es)
BR (1) BR0314286A (es)
CA (1) CA2499332A1 (es)
CO (1) CO5550458A2 (es)
EA (1) EA200500286A1 (es)
EC (1) ECSP055685A (es)
HR (1) HRP20050246A2 (es)
IS (1) IS7695A (es)
MA (1) MA27444A1 (es)
MX (1) MXPA05002378A (es)
NO (1) NO20051852L (es)
OA (1) OA12925A (es)
PA (1) PA8583101A1 (es)
PE (1) PE20050076A1 (es)
PL (1) PL375973A1 (es)
TW (1) TW200410954A (es)
UY (1) UY27983A1 (es)
WO (1) WO2004026865A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2325687T3 (es) * 2002-09-18 2009-09-14 Pfizer Products Inc. Compuestos de imidazol novedosos como inhibidores del factor de crecimiento transformante (tgf).
ES2335099T3 (es) * 2002-09-18 2010-03-22 Pfizer Products Inc. Novedosos compuestos de pirazol como inhibidor del factor de crecimiento transformante (tgf).
WO2004026863A1 (en) 2002-09-18 2004-04-01 Pfizer Products Inc. Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors
PA8595001A1 (es) * 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
MX2007003318A (es) 2004-09-20 2007-05-18 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
WO2006034341A2 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
TW200626138A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
CA2580857A1 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
WO2006034441A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
JP5094398B2 (ja) 2004-09-20 2012-12-12 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環式誘導体およびステアロイル−ＣｏＡデサチュラーゼのメディエータとしてのそれらの使用
WO2006034440A2 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
JP5123671B2 (ja) 2005-02-17 2013-01-23 シンタ ファーマシューティカルズ コーポレーション 増殖性疾患の治療のための化合物
AU2006343359A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
ZA200804496B (en) * 2005-12-16 2009-09-30 Alcon Inc Control of intraocular pressure using ALK5 modulation agents
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
KR102168088B1 (ko) 2013-03-14 2020-10-20 더 브리검 앤드 우먼즈 하스피털, 인크. 상피 줄기 세포 확장 및 배양을 위한 조성물 및 방법
US10030004B2 (en) 2014-01-01 2018-07-24 Medivation Technologies Llc Compounds and methods of use
IL299964A (en) 2014-09-03 2023-03-01 Massachusetts Inst Technology Preparations, systems and methods for producing hair cells in the inner ear to treat hearing loss
EP3313420B1 (en) 2015-06-25 2024-03-13 The Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
CA3010610A1 (en) 2016-01-08 2017-07-13 The Brigham And Women's Hospital, Inc. Production of differentiated enteroendocrine cells and insulin producing cells
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
WO2017161001A1 (en) 2016-03-15 2017-09-21 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
CA3048220A1 (en) 2016-12-30 2018-07-05 Frequency Therapeutics, Inc. 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
US11866427B2 (en) 2018-03-20 2024-01-09 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
WO2019236766A1 (en) 2018-06-06 2019-12-12 Ideaya Biosciences, Inc. Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds
US11617745B2 (en) 2018-08-17 2023-04-04 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating FOXO
EP3837352A1 (en) 2018-08-17 2021-06-23 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating jag-1
US20220162182A1 (en) 2018-12-31 2022-05-26 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5095272A (es) * 1973-12-24 1975-07-29
EP1019394A1 (en) 1997-05-22 2000-07-19 G.D. Searle & Co. PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS
RU2249591C2 (ru) 1997-05-22 2005-04-10 Дж.Д. Серл Энд Ко. 3(5)-гетероарилзамещенные пиразолы в качестве ингибиторов киназы p38
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
JP2002541253A (ja) 1999-04-09 2002-12-03 スミスクライン・ビーチャム・コーポレイション トリアリールイミダゾール
AR029803A1 (es) 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
AU2002225730A1 (en) 2000-11-16 2002-05-27 Smith Kline Beecham Corporation Compounds
GB0027987D0 (en) * 2000-11-16 2001-01-03 Smithkline Beecham Plc Compounds
GB0100762D0 (en) 2001-01-11 2001-02-21 Smithkline Beecham Plc Novel use
WO2002062787A1 (en) * 2001-02-02 2002-08-15 Glaxo Group Limited Pyrazoles as tgf inhibitors
GB0102668D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102672D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
US20040087623A1 (en) * 2001-02-02 2004-05-06 Gellibert Francoise Jeanne Pyrazole derivatives against tgf overexpression
US6673818B2 (en) * 2001-04-20 2004-01-06 Pharmacia Corporation Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
AR040726A1 (es) 2002-07-31 2005-04-20 Smithkline Beecham Corp Compuesto de 2- fenilpiridin-4-il-heterociclico, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento

Also Published As

Publication number Publication date
CN1681809A (zh) 2005-10-12
MA27444A1 (fr) 2005-07-01
PA8583101A1 (es) 2004-04-23
AU2003263431A1 (en) 2004-04-08
PL375973A1 (en) 2005-12-12
KR20050057441A (ko) 2005-06-16
BR0314286A (pt) 2005-08-02
HRP20050246A2 (en) 2005-10-31
OA12925A (en) 2006-10-13
ECSP055685A (es) 2005-05-30
CO5550458A2 (es) 2005-08-31
CA2499332A1 (en) 2004-04-01
NO20051852L (no) 2005-06-16
EP1542995A1 (en) 2005-06-22
UY27983A1 (es) 2004-04-30
US20040116473A1 (en) 2004-06-17
TW200410954A (en) 2004-07-01
IS7695A (is) 2005-02-14
WO2004026865A1 (en) 2004-04-01
US7030125B2 (en) 2006-04-18
EA200500286A1 (ru) 2005-08-25
PE20050076A1 (es) 2005-03-26
AP2005003262A0 (en) 2005-03-31
JP2006506443A (ja) 2006-02-23
MXPA05002378A (es) 2005-05-23

Similar Documents

Publication Publication Date Title
AR041275A1 (es) Compuestos de isotiazol e isoxazol como inhibidores del factor de crecimiento transformador (tgf) y composicion farmaceutica
AR041273A1 (es) Compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf)
AR041274A1 (es) Compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf)
AR041272A1 (es) Compuestos de pirazol como inhibidores del factor de crecimiento transformante (tgf) y composicion farmaceutica que los contiene
AR041276A1 (es) Compuestos de triazol como inhibidores del factor crecimiento transformador (tgf)
AR043449A1 (es) Compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transformante (tgf)
TWI759301B (zh) 聚乙二醇化卡非佐米化合物
AR024060A1 (es) Nuevos compuestos farmaceuticamente activos
AR052938A1 (es) Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor vr1
CZ412898A3 (cs) Substituované cyklopentanové sloučeniny, použitelné jako inhibitory neuraminidázy
RS49906B (sr) Benzociklohepteni, postupak za njihovo dobijanje, farmaceutski preparati koji ove sadrže kao i njihova primena za izradu lekova
CA3130994A1 (en) Derivatives of dolastatin 10 and auristatins
HU229510B1 (en) Pleuromutilin derivatives having antibacterial activity
PA8573501A1 (es) Derivados de benzoxazina y su empleo
ES2090024T3 (es) Compuestos de cefemo y procedimientos para su preparacion.
AR045090A1 (es) Derivados de nicotinamida utiles como inhibidores de pde4
CO5601010A2 (es) Derivados de oxazolidinona, procesos para su preparacion y composiciones farmaceuticas que los contienen
KR910006309A (ko) 인지질 및 인지질 유도체를 유효 성분으로 하는 항비루스성 약제
BRPI0417844A (pt) derivados de amida contendo um substituinte de ciclopropilaminocarbonila, de utilidade como inibidores de citocina
JP2007508301A5 (es)
US20180297966A1 (en) Compounds, compositions, and methods of making and using the same
US20090247472A1 (en) Type 1, 4-naphtoquinone compounds, compositions comprising them and use of these compounds as anti-cancer agents
CA2665347C (en) Process for the preparation of pleuromutilins
US11840495B2 (en) Compositions and methods related to di-substituted bicyclo[2.2.1] heptanamine-containing compounds
US20230271918A1 (en) Substituted 3-amino-4-methylbenzenesulfonamides as small molecule inhibitors of ubiquitin-specific protease 28

Legal Events

Date Code Title Description
FB Suspension of granting procedure